February 2019- Moderna, Inc. initiated the first dose in patients in phase I clinical trial for mRNA-1944, which is an anti-chikungunya antibody for the treatment of chikungunya viral infections.
February 2019- Themis Bioscience received the fast-track designation for MV-CHIK, a vaccine for treating chikungunya viral infections from the United States food and drug administration, FDA.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?